Nonetheless, our results demonstrate that CD40L-B-cell vaccination could induce superior CD8 T-cell responses and antitumor immunity against B16 melanoma compared to DC vaccination (Figures 3B and 5A), indicating that additional expression of CD40L molecules on B-cells achieves enhanced APC function to stimulate antigen-specific T-cells in vivo. The gene discussed is CD8A; the disease is melanoma.